Chronic, recurrent Lymphocytic Leukemia Recruiting Phase 1 / 2 Trials for Obinutuzumab (DB08935)

Also known as: Recurrent Chronic Lymphocytic Leukemia

IndicationStatusPhase
DBCOND0112002 (Chronic, recurrent Lymphocytic Leukemia)Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03010358Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin LymphomaTreatment